m⁶ A 修饰在肝细胞癌药物治疗中作用研究进展. (Chinese)

Research progress in m⁶ A methylation modification in the treatment of hepatocellular carcinoma. (English)

The long-term survival rate of patients with hepatocellular carcinoma (HCC) is poor, and drug efficacy is an important factor affecting clinical prognosis. N6-methyladenosine (m⁶A) modification is the most abundant modification in eukaryotic RNA, which can affect the occurrence and development of HCC and drug efficacy by regulating cancer-related biological functions. However, the role of m⁶A modification in HCC drug treatment has not been fully elucidated. Therefore, the biological functions of different regulatory members of the m⁶A modification process (methyltransferase, demethyltransferase and binding protein) in HCC drug treatment were illustrated, proposing that regulatory members of the m⁶A modification process can be used as biomarkers for HCC prognosis evaluation and have the potential to become therapeutic targets and providing novel insights for HCC precision medicine. [ABSTRACT FROM AUTHOR]

肝细胞癌 (HCC) 患者长期生存率不佳, 药物疗效是影响其预后的重要因素. N6- 甲基腺嘌呤 (m⁶ A) 修饰是真核生物 RNA 中最丰富的修饰, 可通过调节与癌症相关的生物学功能来影响癌症的发生发展及药物疗效. 然 而, m⁶ A 修饰在 HCC 药物治疗中的作用尚未完全阐明, 因此, 文章通过 m⁶ A 修饰过程的 3 种调节成员 (甲基转移酶, 去甲基转移酶和结合蛋白) 来论述其在 HCC 药物治疗中发挥的生物学作用, 进而提出 m⁶ A 修饰调节成员可作为 HCC 预后评估的生物标志物以及具有成为治疗靶点的潜力, 为 HCC 精准医疗提供新的见解. [ABSTRACT FROM AUTHOR]

Copyright of Journal of New Medicine is the property of Sun Yat Sen University and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)